FDA Approves Beech Tree Labs' Oral Herpes IND Application

PROVIDENCE, R.I.--()--Beech Tree Labs, Inc., announced today that the FDA has approved its IND for a Phase 1/2a clinical evaluation of BTL-TML-HSV, a novel therapeutic agent for treating recurrent oral herpes infections. The study will be a 210 patient, multi-site, placebo-controlled trial and is anticipated to begin later this summer.

According to WHO and CDC statistics, over 80 percent of the population have oral herpes with about 20 percent of these expressing symptoms. One if four adults has genital herpes, with the incidence steadily increasing.

Herpes simplex, the virus causing oral herpes, serves as the prototype of a Beech Tree Labs' approach that potentially addresses a broad spectrum of herpesvirus indications. The active agent is also embodied in a product candidate that recently received FDA approval of an IND targeting influenza, presenting evidence of a growing Beech Tree anti-viral platform.

Beech Tree Labs is a privately held biopharmaceutical company specializing in discovery and early-stage development through Phase 2 clinical trials, followed by licensing to larger pharmaceutical and biotech firms for late-stage evaluation and marketing. It is a leader in resonant molecular signaling technology and holds a number of patents on other potential therapeutics.

Contacts

Beech Tree Labs, Inc.
Kenneth Smith, Communications Director
804-594-3661
Fax: 804-594-0575
ksmith@beechtreelabs.com

For more on Beech Tree Labs: www.beechtreelabs.com

Release Summary

Beech Tree Labs, Inc., announced today that the FDA has approved its IND for a Phase 1/2a clinical evaluation of BTL-TML-HSV, a novel therapeutic agent for treating recurrent oral herpes infections.

Contacts

Beech Tree Labs, Inc.
Kenneth Smith, Communications Director
804-594-3661
Fax: 804-594-0575
ksmith@beechtreelabs.com

For more on Beech Tree Labs: www.beechtreelabs.com